Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Autor: M, Pérol, E, Felip, U, Dafni, L, Polito, N, Pal, Z, Tsourti, T G N, Ton, D, Merritt, S, Morris, R, Stahel, S, Peters

Publikováno v: Annals of Oncology. 33:511-521

Anti-programmed cell death protein (death-ligand) 1 [PD-(L)1] therapy alone [cancer immunotherapy (CIT)-mono] or combined with platinum-based chemotherapy (CIT-chemo) is used as the first-line treatment for patients with metastatic non-small-cell lun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0597706ea488988e41e8195dbf66cee6
https://doi.org/10.1016/j.annonc.2022.02.008

A tribute to Dr Vittorio (Orio) Giarini, 31 January 1936–28 February 2020. A great European and a close friend

Autor: Walter R Stahel

Publikováno v: The Geneva Papers on Risk and Insurance. Issues and Practice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df94317a4e638719bac268899f906fa9
http://europepmc.org/articles/PMC8005857

405P Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019

Autor: R. Soo, L. Mery, A. Bardot, R. Kanesvaran, T. Keong, D. Pongnikorn, N. Prasongsook, S. Hutajulu, C. Irawan, A. Ab Manan, M. Thiagarajan, P. Sripan, S. Peters, H. Storm, F. Bray, R. Stahel

Publikováno v: Annals of Oncology. 33:S1600-S1601

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5dfbe19a7857b9a9b79a17c7c8787f77
https://doi.org/10.1016/j.annonc.2022.10.436

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Autor: S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press

BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c0cd2636f83c5b87a3871c7a3d45ee
https://lirias.kuleuven.be/handle/123456789/682788

Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries

Autor: R, Soo, L, Mery, A, Bardot, R, Kanesvaran, T C, Keong, D, Pongnikorn, N, Prasongsook, S H, Hutajulu, C, Irawan, A Ab, Manan, M, Thiagarajan, P, Sripan, S, Peters, H, Storm, F, Bray, R, Stahel

Publikováno v: ESMO Open. 7:100560

Lung cancer is the second most common cancer and leading cause of cancer mortality worldwide. Recent advances in molecular testing and targeted therapy have improved survival among patients with metastatic non-small-cell lung cancer (NSCLC). We sough

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f508a63f79c0a8b47dc6a9a68cfc08d7
https://doi.org/10.1016/j.esmoop.2022.100560